Literature DB >> 24375894

Marker (+) CNS germ cell tumors in remission: are surveillance MRI scans necessary?

Sybila Martinez1, Yasmin Khakoo, Stephen Gilheeney, Kim Kramer, Suzanne Wolden, Mark Souweidane, Ira J Dunkel.   

Abstract

BACKGROUND: Patients with marker (+) CNS germ cell tumors are usually followed with both surveillance MRI scans and serum tumor markers. We hypothesized that patients with elevated serum tumor markers at diagnosis who achieve a complete biochemical and radiological remission may not need surveillance MRI scans. PROCEDURE: We retrospectively identified 31 patients with CNS germ cell tumors who presented with an elevated serum tumor marker at the time of diagnosis. We reviewed the records of those patients who (1) achieved a complete biochemical and radiological remission and (2) later suffered tumor recurrence to determine whether the recurrence was detectable biochemically, radiologically, or via both modalities.
RESULTS: Nine patients suffered tumor recurrence following initial remission. All 9 had elevated serum tumor markers at recurrence and 8 had MRI evidence of recurrence. The 1 patient with isolated biochemical evidence of recurrence developed MRI evidence of recurrence 15 months later without intervening treatment. One other patient (not one of the 9) had a secondary malignancy (anaplastic astrocytoma) identified by brain MRI scan.
CONCLUSIONS: Patients with CNS germ cell tumors who present with elevated serum tumor markers at diagnosis and achieve a complete biochemical and radiological remission may not need surveillance MRI scans to monitor for recurrence, but MRI scans may be considered to monitor for secondary malignancy. If other series replicate these findings, surveillance via monitoring of serum tumor markers only could be done and omission or reduction of the frequency of surveillance MRI scans could save a significant amount of money.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  CNS tumors; germ cell tumors; radiology; tumor markers

Mesh:

Substances:

Year:  2013        PMID: 24375894     DOI: 10.1002/pbc.24888

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  2 in total

1.  Utility of MRI versus tumor markers for post-treatment surveillance of marker-positive CNS germ cell tumors.

Authors:  Victoria Cheung; Devorah Segal; Sharon L Gardner; David Zagzag; Jeffrey H Wisoff; Jeffrey C Allen; Matthias A Karajannis
Journal:  J Neurooncol       Date:  2016-07-12       Impact factor: 4.130

Review 2.  Advances in the management of central nervous system germ cell tumors.

Authors:  Nathan E Millard; Ira J Dunkel
Journal:  Curr Oncol Rep       Date:  2014-07       Impact factor: 5.945

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.